Quarterly ResultMay 13, 2026, 07:02 AM
BeyondSpring Q1 2026 Net Loss $2.4M; Plinabulin & SEED Progress
AI Summary
BeyondSpring Inc. reported a net loss of $2.4 million from continuing operations for Q1 2026, an improvement from $2.6 million in Q1 2025. However, the overall net loss attributable to BeyondSpring Inc. was $2.16 million, a significant change from net income of $4.48 million in Q1 2025, largely due to a $4.3 million loss from discontinued operations. The company also provided a corporate update, highlighting positive preclinical data for Plinabulin and the advancement of SEED Therapeutics' ST-01156 into Phase 1 clinical development.
Key Highlights
- Net loss from continuing operations was $2.4 million for Q1 2026, compared to $2.6 million in Q1 2025.
- R&D expenses increased to $1.1 million in Q1 2026 from $0.9 million in Q1 2025.
- G&A expenses decreased to $1.1 million in Q1 2026 from $1.7 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $7.9 million as of March 31, 2026.
- Net loss from discontinued operations was $4.3 million in Q1 2026, compared to net income of $3.8 million in Q1 2025.
- Plinabulin AACR 2026 data demonstrated enhanced efficacy and tolerability in ADC regimens.
- SEED Therapeutics' ST-01156 advanced into Phase 1 clinical development, completing the first dose cohort.
- Basic and diluted loss per share was $0.05 for Q1 2026, compared to earnings of $0.11 for Q1 2025.